Schizophrenia
is a persistent long-term brain disorder that causes severe, debilitating
psychotic episodes. Its core symptoms, auditory or visual hallucinations, are
often accompanied by fixed, false, and often paranoid beliefs, called
delusions. These two features are often combined with learning and cognitive
deficits. WHO experts have estimated that roughly 24 million people are
affected by schizophrenia worldwide.
While
the arrival of atypical antipsychotics has greatly expanded pharmacologic
treatment options over the past two decades, the current drug market does not
treat the negative and cognitive symptoms that are associated with the disease.
GlobalData expects that the growing popularity of long-acting injectable (LAI)
antipsychotics, along with the arrival of novel treatments that achieve higher
efficacy in negative- and cognitive-predominant patients, will serve to
stimulate growth in the marketplace over the forecast period. Country-specific
treatment recommendations and policy implementation will be an essential metric
for determining future mental health services in the 7MM.
Access This Full Report @ http://www.radiantinsights.com/research/risperdal-schizophrenia-forecast-and-market-analysis-to-2022
Risperdal
(risperidone; Janssen) is a potent 5-HT2A/D2 receptor antagonist, with a higher
relative affinity for 5-HT2A over D2 and D3 receptors. Risperdal was first
approved by the FDA in 1993 and was the first antipsychotic approved after
clozapine. After establishing a solid claim of the atypical antipsychotics
market throughout the late 1990s and early 2000s, the development of
long-acting injectable Risperdal Consta has helped the brand survive patent
expirations to older formulations.
Scope
-
Overview of Schizophrenia, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on the
competitive landscape.
-
Detailed information on Risperdal including product description, safety and
efficacy profiles as well as a SWOT analysis.
-
Sales forecast for Risperdal for the top seven countries from 2012 to 2022.
-
Sales information covered for the US, France, Germany, Italy, Spain, the UK and
Japan
Reasons
to buy
-
Understand and capitalize by identifying products that are most likely to
ensure a robust return
-
Stay ahead of the competition by understanding the changing competitive
landscape for Schizophrenia
-
Effectively plan your M&A and partnership strategies by identifying drugs
with the most promising sales potential
-
Make more informed business decisions from insightful and in-depth analysis of
Risperdal performance
-
Obtain sales forecast for Risperdal from 2012-2022 in the top seven countries
(the US, France, Germany, Italy, Spain, the UK and Japan)
About
Us
Radiant Insights is a platform
for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure
market research reports, helping them in the decision making process. We have a
comprehensive collection of reports, covering over 40 key industries and a host
of micro markets. In addition to over extensive database of reports, our
experienced research coordinators also offer a host of ancillary services such
as, research partnerships/ tie-ups and customized research solutions.
For
more information visit: Radiant
Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
Blog URL: http://www.esorics2010.org/
No comments:
Post a Comment